Dendritic Cell Therapy for Mesothelioma: Can it Help Other Treatments Work Better?
| | | | |

Dendritic Cell Therapy for Mesothelioma: Can it Help Other Treatments Work Better?

A new kind of mesothelioma treatment called dendritic cell therapy might make other types of treatments even more effective.  Right now, chemotherapy with Alimta (pemetrexed) is the only approved therapy for malignant mesothelioma. Many others are in the works. But so far, none of them extend the lives of mesothelioma patients by more than a few months.  Dendritic cell therapy for mesothelioma may be different. This novel treatment uses the patient’s own cells to jumpstart the immune system.  A Dutch company developed and is testing the new treatment. The data so far suggests that it could boost chemotherapy and help new drugs like Keytruda work better.  How Dendritic Cell Therapy Works Dendritic cells are immune system cells that function as…

New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy
| | | | | |

New Mesothelioma Clinical Trial Will Test Personalized Immunotherapy

A Dutch company has recruited the first patients into a pivotal mesothelioma clinical trial of autologous dendritic cells. Dendritic cells are immune system cells that work as messengers. They help tell T cells to attack cancers like malignant mesothelioma. The new mesothelioma clinical trial will test using the patient’s own dendritic cells (autologous cells) as a way to keep cancer from coming back after mesothelioma treatment. Expanding Mesothelioma Treatment Options There is only one approved treatment for malignant pleural mesothelioma. This “standard of care” treatment is chemotherapy with Alimta (pemetrexed) and cisplatin. Although most mesothelioma patients receive this treatment, very few live longer than a year after diagnosis. A Netherlands-based company called Amphera is trying to change those odds. Its…